BMRN BioMarin Pharmaceutical Inc. featured news, full reports, and detailed charts
BioMarin Pharmaceutical Inc. (BMRN) Wrap Up:
BioMarin Pharmaceutical, Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises approved products and multiple investigational product candidates. Its approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of genetic disease called mucopolysaccharidosis VI; Kuvan (sapropterin dihydrochloride), a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase indicated for patients with Phenylketonuria (PKU); and Aldurazyme (laronidase) that is used for the treatment of mucopolysacch...BioMarin Pharmaceutical Inc. (BMRN:NASDAQ)
Snapshot of BioMarin Pharmaceutical Inc. (BMRN)
|
OPEN
$17.25
|
PREVIOUS CLOSE
$17.34
|
|
|
DAY HIGH
$17.25
|
DAY LOW
$16.92
|
|
|
52 WEEK HIGH
01/16/09 - $21.23
|
52 WEEK LOW
03/6/09 - $9.93
|
|
|
MARKET CAP
1.7B
|
AVERAGE VOLUME 3 mo
875.5K
|
|
|
DILUTED EPS TTM
$0.14
|
SHARES OUTSTANDING
100.7M
|
|
|
BMRN Does Not Pay Dividends
|
P/E TTM
125.6x
|
|
| K = Thousands M = Millions B = Billions | ||
related news
BMRN Top Compensated Officers
Executives, Board Directors
Key developments for BioMarin Pharmaceutical Inc. (BMRN)
To present a company update
BioMarin Pharmaceutical Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported GAAP net income was $6.6 million or $0.06 per diluted share as compared to GAAP net income of $0.8 million or $0.01 per diluted share for the third quarter of 2008. Non-GAAP net income was $15.5 million or $0.13 per diluted share for the third quarter of 2009, compared to non-GAAP net income of $8.2 million or $0.08 per diluted share for the third quarter of 2008. The company reported total revenues of $80,807,000 as compared to $72,646,000 for the same period last year. Income from operations was $10,133,000 and income before income taxes was $7,585,000 as compared to income from operations of $2,351,000 and income before income taxes of $1,081,000 for the same period last year. For nine months, the company reported GAAP net loss was $5.2 million or $0.05 per diluted share, compared to GAAP net income of $6.3 million or $0.06 per diluted share for the nine months ended September 30, 2008. Non-GAAP net income was $33.9 million or $0.33 per diluted share for the nine months ended September 30, 2009, compared to non-GAAP net income of $21.9 million or $0.21 per diluted share for the nine months ended September 30, 2008. The company reported total revenues of $237,574,000 as compared to $197,217,000 for the same period last year. Income from operations was $10,045,000 and income before income taxes was $3,315,000 as compared to income from operations of $7,700,000 and income before income taxes of $6,868,000 for the same period last year. The company revised earnings guidance for the full year of 2009. For the period, the company expects total revenues to range of $313 to $327 as compared $311 to $336 of the previous guidance, GAAP net loss to range between $8 to $4 and non-GAAP net income to range between $39.8 to $43.8 as compare to GAAP net loss $12 to $6 and non-GAAP net income of $35.4 to $41.4 of the previous guidance.
To present a company update
BMRN Competitors
| Company | Last | Change |
| Biogen Idec Inc | $46.38 USD | +0.53 |
| Celera Group | $6.25 USD | -0.05 |
| Genzyme Corp | $50.05 USD | +0.42 |
| Shire | 1,135 GBX | +16.00 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | BMRN | Industry Range |
| Price/Earnings | 90.5x |
|
| Price/Sales | 5.2x |
|
| Price/Book | 5.7x |
|
| Price/Cash Flow | 74.9x |
|
| TEV/Sales | 2.6x |
|
|
BMRN |
||
BMRN transactions
| Type Date |
Target |
|
Merger/Acquisition
October 20, 2009 |
Huxley Pharmaceuticals, Inc. |